p16 immunohistochemistry of multiple primary melanomas as screening to identify Familial Melanoma Syndrome.
作者信息
Ponti Giovanni, Luppi Gabriele, Losi Lorena, Cesinaro Anna Maria, Sartori Giuliana, Maiorana Antonio, Pellacani Giovanni, Longo Caterina, Boni Elisa, Pepe Patrizia, Giannetti Alberto, Seidenari Stefania, Landi Maria Teresa
出版信息
Int J Dermatol. 2012 Apr;51(4):488-92. doi: 10.1111/j.1365-4632.2010.04496.x. Epub 2011 Jun 15.
Abstract
摘要
相似文献
1
p16 immunohistochemistry of multiple primary melanomas as screening to identify Familial Melanoma Syndrome.多原发性黑色素瘤的p16免疫组织化学检测作为筛查手段以识别家族性黑色素瘤综合征
Int J Dermatol. 2012 Apr;51(4):488-92. doi: 10.1111/j.1365-4632.2010.04496.x. Epub 2011 Jun 15.
2
Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer.有胶质瘤、恶性黑色素瘤、结肠癌和乳腺癌家族病史的家族中的种系重排。
Neuro Oncol. 2014 Oct;16(10):1333-40. doi: 10.1093/neuonc/nou052. Epub 2014 Apr 9.
3
Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients.家族性黑色素瘤患者黑素细胞性病变中突变型p16蛋白的表达与定位
Hum Pathol. 2004 Jan;35(1):25-33. doi: 10.1016/j.humpath.2003.08.017.
4
An analysis of p16 protein expression in sporadic malignant melanoma.散发性恶性黑色素瘤中p16蛋白表达的分析
Melanoma Res. 1998 Jun;8(3):267-72. doi: 10.1097/00008390-199806000-00010.
5
Expression and significance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma.p53、rb、p21/waf-1、p16/ink-4a和PTEN肿瘤抑制因子在犬黑色素瘤中的表达及意义
Vet Pathol. 2002 Jul;39(4):458-72. doi: 10.1354/vp.39-4-458.
6
Application of in situ hybridization probes for MLH-1 and MSH-2 in tissue microarrays of paraffin-embedded malignant melanomas: correlation with immunohistochemistry and tumor stage.原位杂交探针在石蜡包埋恶性黑色素瘤组织微阵列中检测MLH-1和MSH-2的应用：与免疫组织化学及肿瘤分期的相关性
Hum Pathol. 2004 Dec;35(12):1543-8. doi: 10.1016/j.humpath.2004.09.016.
7
Germline CDKN2A/p16 mutations are rare in multiple primary and familial malignant melanoma in German patients.在德国患者中，种系CDKN2A/p16突变在多发性原发性和家族性恶性黑色素瘤中较为罕见。
J Dermatol Sci. 2008 Feb;49(2):163-5. doi: 10.1016/j.jdermsci.2007.08.006. Epub 2007 Sep 24.
8
CDKN2A/CDK4 molecular study on 155 Italian subjects with familial and/or primary multiple melanoma.对155名患有家族性和/或原发性多发性黑色素瘤的意大利受试者进行的CDKN2A/CDK4分子研究。
Pigment Cell Melanoma Res. 2008 Apr;21(2):209-11. doi: 10.1111/j.1755-148X.2008.00446.x. Epub 2008 Mar 18.
9
10
Lack of inherited mutations of PTPRD in familial melanoma and melanoma-astrocytoma syndrome.家族性黑色素瘤和黑色素瘤-星形细胞瘤综合征中缺乏PTPRD的遗传性突变。
Pigment Cell Melanoma Res. 2009 Aug;22(4):489-91. doi: 10.1111/j.1755-148X.2009.00587.x. Epub 2009 Jun 3.
引用本文的文献
1
Mutational status of naevus-associated melanomas.痣相关黑色素瘤的突变状态。
Br J Dermatol. 2015 Sep;173(3):671-80. doi: 10.1111/bjd.13829. Epub 2015 Jun 19.
本文引用的文献
1
Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas.多原发性黑色素瘤患者中基于人群的CDKN2A和CDK4突变患病率。
Genes Chromosomes Cancer. 2008 Feb;47(2):175-84. doi: 10.1002/gcc.20518.
2
Monitoring stage-specific trends in melanoma incidence across Europe reveals the need for more complete information on diagnostic characteristics.监测欧洲黑色素瘤发病率的特定阶段趋势表明，需要更全面的诊断特征信息。
Eur J Cancer Prev. 2004 Oct;13(5):387-95. doi: 10.1097/00008469-200410000-00006.
3
Genetic susceptibility in familial melanoma from northeastern Italy.意大利东北部家族性黑色素瘤的遗传易感性。
J Med Genet. 2004 Jul;41(7):557-66. doi: 10.1136/jmg.2003.016907.
4
Electron microscopy evidence that cytoplasmic localization of the p16(INK4A) "nuclear" cyclin-dependent kinase inhibitor (CKI) in tumor cells is specific and not an artifact. A study in non-small cell lung carcinomas.电子显微镜证据表明，肿瘤细胞中p16(INK4A)“核”细胞周期蛋白依赖性激酶抑制剂（CKI）的细胞质定位具有特异性，并非人为现象。一项针对非小细胞肺癌的研究。
Biotech Histochem. 2004 Feb;79(1):5-10. doi: 10.1080/10520290310001659466.
5
Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients.家族性黑色素瘤患者黑素细胞性病变中突变型p16蛋白的表达与定位
Hum Pathol. 2004 Jan;35(1):25-33. doi: 10.1016/j.humpath.2003.08.017.
6
Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study.皮肤恶性黑色素瘤的进展与不同的表达谱相关：一项基于组织微阵列的研究。
Am J Pathol. 2004 Jan;164(1):193-203. doi: 10.1016/s0002-9440(10)63110-0.
7
CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.患有多发性皮肤黑色素瘤个体中的CDKN2A种系突变。
Cancer Res. 2000 Dec 15;60(24):6864-7.
8
High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.CDKN2A突变阳性黑色素瘤家族中多发性黑色素瘤及乳腺癌和胰腺癌的高发病率。
J Natl Cancer Inst. 2000 Aug 2;92(15):1260-6. doi: 10.1093/jnci/92.15.1260.
9
Second primary tumors in patients with cutaneous malignant melanoma.皮肤恶性黑色素瘤患者的第二原发性肿瘤
Cancer. 1999 Nov 15;86(10):2014-20. doi: 10.1002/(sici)1097-0142(19991115)86:10<2014::aid-cncr19>3.0.co;2-4.
10
p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry.通过免疫组织化学检测黑素细胞肿瘤中p16和p21WAF1蛋白的表达。
Am J Dermatopathol. 1998 Jun;20(3):255-61. doi: 10.1097/00000372-199806000-00006.
Zotero 插件